DEVINTEC SAGL
Switzerland CH-MF-000020271 Last updated 21 Oct 2026
- Devices
- 33
- Registries
- EUDAMED
- FDA recalls
- 0
Catalogue
Fybocalm Wind & Bloating Relief Ref C12B02E015
Gelsectan Ibutin Ref C05B02E030
Gavidigest Diarrhèe Ref C05B02E060
Gavidigest Gases e hinchazon Ref C12B02E03
Dermasectan Ref C41E07L100
Vivesse Ref C04E07M005
Gelsectan Ibutin Ref C05B02E015
Fybocalm Wind & Bloating relief Ref C12B02E030
Gaviscon Intestino Stitichezza Ref C20B02E008
Gaviscon Intestino Gonfiore e meteorismo Ref C12B02E030
Fybocalm Constipation relief Ref C20B02E030
Gavidarm Häufige Verstopfung Ref C20B02E008
Dermasectan Ref C41E07L050
Gelsectan Ref C05B02E060
Gavidigest Estrenimiento Ref C20B02E030
Gavidigest Diarrhée Ref C05B02E030
Gavidigest Constipation Ref C20B02E060
Gelsectan Ref C05B02E008
Gaviscon Intestino Stitichezza Ref C20B02E030
Gavidigest Gases e inchaço Ref C12B02E003
Gavidarm Häufige Verstopfung Ref C20B02E030
Gelselax Ref C20B02E030
Sorisen Ref C43E07L100
Gavidigest Gases e hinchazon Ref C12B02E030
Fybocalm Diarrhoea Relief Ref C05B02E030
Gavidigest Constipation Ref C20B02E030
Sectacol Ref C12B02E003
GAVIDigest FLATULENCES & BALLONNEMENTS Ref C12B02E030
Sectacol Ref C12B02E030HU
Lefaxan Protect Ref C12B02E015
Dermasectan Ref C41E07L003
Gavidigest Diarreia Ref C05B02E030
Gavidarm Häufiger Durchfall Ref C05B02E008
EUDAMED certificates
BUREAU VERITAS ITALIA S.P.A. 1370 3 certificates
- IT325651 Supplemented
Quality management system EU MDR
- Issued
- 26 Sep 2025
- Expires
- 7 Sep 2028
- Reason
- Other
- IT326645 Supplemented
Technical documentation EU MDR
- Issued
- 18 Mar 2025
- Expires
- 7 Sep 2028
- Reason
- Add device or group
- IT336677 Issued
Quality management system EU MDR
- Issued
- 22 Oct 2024
- Expires
- 7 Sep 2028
Related companies
Authorised representatives
Notified bodies
About
Devintec is a privately owned pharmaceutical company based in Switzerland pioneer in research and developing innovative substance-based medical devices.
What DEVINTEC SAGL makes
Devintec SAGL manufactures gastrointestinal and dermatological medical devices, including antacids and anti-gas formulations like Fybocalm for wind and constipation relief, Gelsectan for pain relief, and Gaviscon for intestinal bloating. Their portfolio also includes treatments for diarrhea (Gavidigest) and topical dermatological products such as Dermasectan. Additionally, they produce Vissect, a substance-based medical device for unspecified gastrointestinal applications.
The company’s devices are classified under EU medical device regulations as Class IIa and Class III, with all products listed in the EUDAMED database. Devintec SAGL is based in Switzerland and adheres to European regulatory requirements for medical devices.
Frequently asked questions
What types of medical devices does Devintec SAGL manufacture?
Devintec SAGL specializes in gastrointestinal and dermatological medical devices. Their portfolio includes antacids and anti-gas formulations like Fybocalm (for wind and constipation relief), Gelsectan (for pain relief), and Gaviscon (for intestinal bloating). They also produce treatments for diarrhea (Gavidigest) and topical dermatological products such as Dermasectan. Additionally, they develop Vissect, a substance-based device for gastrointestinal applications.
Where is Devintec SAGL based, and what regulatory framework does it follow?
Devintec SAGL is based in Switzerland and operates under European medical device regulations. Since their devices are listed in the EUDAMED database, they comply with the EU Medical Device Regulations (MDR), which classify their products as either Class IIa or Class III based on risk levels.
Which regulatory registries list Devintec SAGL’s medical devices?
Devintec SAGL’s medical devices are listed in the EUDAMED database, which is the European Union’s central registry for medical device information. This registry ensures transparency and traceability of devices authorized under EU medical device regulations.
How are Devintec SAGL’s devices classified under EU regulations?
Devintec SAGL’s devices are classified as either Class IIa or Class III under the EU Medical Device Regulations. The classification depends on the risk associated with the device’s intended use—Class III includes higher-risk devices requiring stricter scrutiny, while Class IIa covers moderate-risk products.
Information
- Country
- Switzerland
- Address
- 14, Corso Elvezia, Lugano, Switzerland
- Website
- www.devintecpharma.com
- [email protected]
- Phone
- 0041916014051
- PRRC contact
- Simone Brancè
- EUDAMED SRN
- CH-MF-000020271